SQSTM1 and liver cancer: Mechanistically, it has been shown to suppress PSC activation, resulting in stromal remodeling and increased intratumoral gemcitabine effects in PDAC, while interaction between VDR and p62/SQSTM1 suppressed HSC activation and liver cancer (Sherman et al., 2014; Duran et al., 2016).